--- title: "Mazdutide Peptide SA - Compare Prices from 0 Suppliers - PeptideSupermarket®" description: "Compare Mazdutide prices from 0 SA suppliers. Find the cheapest deals, read reviews and save money." url: "https://peptidesupermarket.co.za/peptide/mazdutide" site: "PeptideSupermarket®" country: "South Africa" --- [Home](https://peptidesupermarket.co.za) › [Peptides](https://peptidesupermarket.co.za/compare-peptide-prices-za) › Mazdutide Search # Mazdutide Price Comparison Live prices from 0 SA suppliers, compared side by side so you never overpay. [GLP-1 & metabolic research](https://peptidesupermarket.co.za/compare-peptide-prices-za) We compare prices & may earn a commission. [Full disclosure](https://peptidesupermarket.co.za/disclosure). 0 results ### No products found We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly. More ways to compare Mazdutide Different views of the same live SA pricing, tuned for how you like to shop. [Best Mazdutide Prices Best prices ranked](https://peptidesupermarket.co.za/best-mazdutide-prices) [Cheapest Mazdutide Prices Cheapest suppliers compared](https://peptidesupermarket.co.za/cheapest-mazdutide-prices) [Where to Buy Mazdutide Full buyer's guide](https://peptidesupermarket.co.za/where-to-buy-mazdutide) [Buy Mazdutide Online SA Cheap Today's hottest deals](https://peptidesupermarket.co.za/buy-mazdutide-online-za-cheap) [Mazdutide Price Comparison Live price dashboard](https://peptidesupermarket.co.za/mazdutide-price-comparison) [Mazdutide SA Supplier Verified SA supplier directory](https://peptidesupermarket.co.za/mazdutide-za-supplier) [Mazdutide For Sale Browse listings for sale](https://peptidesupermarket.co.za/mazdutide-for-sale) Compare another peptide Search PeptideSupermarket® compares prices but doesn't sell products. More All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed. We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed. By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. [Read our full disclosure](https://peptidesupermarket.co.za/disclosure). ## Mazdutide Profile Extensively Studied Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes ### Overview First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control. ### Mechanism of Action Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects. ### Key Benefits - Up to 20% body weight loss - Superior glycemic control versus semaglutide - Increased energy expenditure via glucagon receptor activation - Improved cardiometabolic markers (BP, lipids, liver fat) - Once-weekly injection convenience ### Quick Stats Typical Dose Start 1.5-3mg weekly, titrate up to 6-9mg based on response Frequency Once weekly injection Cycle Duration 48-60+ weeks for optimal results per clinical trials Storage Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution ## Molecular Information Molecular Weight 4,563.1 Da Length 33 amino acids Type Oxyntomodulin analog with fatty acid conjugation Half-Life 6-8 days ### Amino Acid Sequence `33-amino acid linear synthetic peptide` ### Modifications C20 fatty diacid conjugation via hydrophilic linker at Lys20 for extended half-life ## Research Indications The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research. Weight Loss Type 2 Diabetes Cardiovascular ## Dosing Protocols ### injectable Subcutaneous injection delivering dual GLP-1/glucagon agonism with once-weekly dosing enabled by fatty acid conjugation. | Goal | Dose | Frequency | Route | | --- | --- | --- | --- | | Weight loss initiation (3mg target) | 1.5mg → 3mg | Once weekly | SubQ | | Weight loss progression (4.5mg target) | 1.5mg → 3mg → 4.5mg | Once weekly | SubQ | | Weight loss optimization (6mg target) | 2mg → 4mg → 6mg | Once weekly | SubQ | | Maximum weight loss (9mg target) | 3mg → 6mg → 9mg | Once weekly | SubQ | | T2D management (mild-moderate) | 3-4.5mg weekly | Once weekly | SubQ | #### Key Tips - Once-weekly injection convenience - Proven efficacy in Phase 3 trials - Superior results versus semaglutide Reconstitution Instructions ## Peptide Interactions #### Semaglutide Avoid Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk. #### Tirzepatide Avoid Both target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk. #### Liraglutide Avoid Another GLP-1 agonist; dual therapy contraindicated due to additive receptor activation. #### Insulin Monitor May require significant dose reduction due to improved glucose control; monitor for hypoglycemia. #### Sulfonylureas Monitor Increased hypoglycemia risk; dose reduction may be necessary. #### Metformin Synergistic Complementary mechanisms; clinical trials allowed stable metformin use with enhanced efficacy. #### BPC-157 Compatible No known interactions; may support gut health and potentially reduce GI side effects. #### Oral Contraceptives Monitor Delayed gastric emptying may affect absorption; separate administration by 1 hour. ## What to Expect Week 1-2 Appetite reduction, possible mild nausea, decreased portion sizes Week 3-4 Early weight loss begins (1-2%), improved satiety after meals Week 4-8 Dose escalation phase, GI symptoms typically improving, 3-5% weight loss Week 8-16 Steady weight loss continues (7-12%), energy expenditure effects evident Week 16-32 Significant weight reduction (12-17%), metabolic markers improving Week 32-60 Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose ## Side Effects & Safety #### Common Side Effects - Nausea (mild-moderate, typically improves over time) - Diarrhea - Vomiting - Increased heart rate (5-17 bpm observed) #### Monitoring - Start with lowest dose, escalate gradually every 4 weeks - Monitor blood glucose if taking insulin or sulfonylureas - Watch for pancreatitis symptoms - Monitor thyroid function - Maintain adequate hydration during initial weeks #### Stop Signs - Severe or persistent abdominal pain (potential pancreatitis) - Neck lumps, hoarseness, or difficulty swallowing - Severe nausea/vomiting preventing adequate nutrition or hydration - Signs of severe hypoglycemia (confusion, sweating, shakiness) - Severe allergic reactions (rash, difficulty breathing, facial swelling) - Unusual mood changes, depression, or suicidal thoughts - Signs of gallbladder problems (severe upper right abdominal pain) #### Contraindications - Personal or family history of medullary thyroid carcinoma - MEN2 syndrome history (class warning for GLP-1 agonists) - Pregnancy or breastfeeding (insufficient safety data) ## Quality Checklist #### Good Signs - White to off-white lyophilized powder without clumping or discoloration - Completely clear and colorless appearance after reconstitution—no visible particles - Intact vial seal and clear labeling with mg dosage, batch numbers, expiration dates #### Warning Signs - Source verification critical—available from research chemical suppliers #### Bad Signs - Clumping, discoloration, or moisture in powder - Persistent cloudiness or particles after reconstitution indicates degradation ## Research & References ### Key References 1. 2025 #### GLORY-1 Phase 3 Trial 610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM. 2. 2025 #### GLORY-2 Phase 3 Trial 462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed. 3. 2025 #### DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide 349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001). 4. 2024 #### Phase 2 T2D Trial Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care. [Search PubMed for Mazdutide](https://pubmed.ncbi.nlm.nih.gov/?term=%28%22Mazdutide%22%20OR%20%22IBI362%22%20OR%20%22LY3305677%22%29) --- *Add `.md` to any page URL on peptidesupermarket.co.za for its Markdown version. Index of the site: https://peptidesupermarket.co.za/llms.txt - full text: https://peptidesupermarket.co.za/llms-full.txt.*